Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Sarepta Therapeutics Provides Clinical Updates for ELEVIDYS
Date: November 25, 2025
Attention: Providers
Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that the Health and Human Services Commission (HHSC) has been made aware of several key updates for the drug:
A boxed warning for the risk of acute serious liver injury and acute liver failure
Removal of the non-ambulatory indication from the “Indication and Usage” section of the Prescribing Information
Expanded guidance for prescribers, including a modified pre- and post-infusion oral corticosteroids regimen, and enhanced monitoring recommendations every week for 3 months post-infusion
A new Warnings & Precaution regarding increased susceptibility to serious infections due to immunosuppression
Background: ELEVIDYS (Delandistrogene moxeparvovec-rokl) (HCPCS code J1413) is an adeno-associated virus vector-based gene therapy indicated for the treatment of individuals aged four years or older with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.
Previously posted TCHP communication on this important topic is available by clicking here.
Next step for Providers: Providers should follow the guidance found in this communication and the following link elevidys.com/pi for prescribing information.
